Clinical Advances in Hematology & Oncology

09/25/2020

The September issue is available online https://www.hematologyandoncology.net/

06/29/2020

Our June issue is now available online https://www.hematologyandoncology.net/

05/11/2020

Our May issue is now available online https://www.hematologyandoncology.net/

02/19/2020

The February issue is on our site - enjoy! https://www.hematologyandoncology.net/

11/08/2019

Current Issue – Hematology & Oncology

The November issue is available on our website https://www.hematologyandoncology.net/current-issue/

H&O What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR […]

10/01/2019

Current Issue – Hematology & Oncology

The September issue of Clinical Advances in Hematology & Oncology is now available https://www.hematologyandoncology.net/current-issue

  H&O Which patients are eligible for treatment with alpelisib? HR One of the major advances this year in treating hormone receptor (HR)-positive breast cancer has […]

08/08/2019

The August issue of Clinical Advances in Hematology & Oncology is now available https://www.hematologyandoncology.net/current-issue

07/23/2019

Current Issue – Hematology & Oncology

The July issue of Clinical Advances in Hematology & Oncology is available on our site.

  H&O What is prostate-specific membrane antigen (PSMA), and what makes it a good target for staging and treatment in prostate cancer? MH PSMA is a […]

06/18/2019

The June issue is now available on our site http://www.hematologyandoncology.net/current-issue

05/16/2019

Current Issue – Hematology & Oncology

The May issue is available on our website
http://www.hematologyandoncology.net/current-issue/

  H&O Which immunotherapy agents have been approved for use in colorectal cancer (CRC) with mismatch repair deficiency (MMR-D)? MO We have a choice of 3 […]

03/22/2019

The March issue of Clinical Advances in Hematology & Oncology is available on our website. http://www.hematologyandoncology.net/

03/01/2019

Hematology & Oncology – Hematology & Oncology

The February issue is available on our website

  H&O How does the National Institute for Health and Care Excellence assign value to drugs and select the ones that will be covered by the […]

02/01/2019

Hematology & Oncology – Hematology & Oncology

The January issue of Clinical Advances in Hematology & Oncology is available on our site. http://www.hematologyandoncology.net/

  H&O How is erythrocytosis defined? JP Erythrocytosis is the presence of too many red blood cells. Several different parameters are used to diagnose erythrocytosis in […]

11/19/2018

Hematology & Oncology – Hematology & Oncology

The November issue is now available on our site

  H&O How common is human epidermal growth factor receptor 2 (HER2) amplification in metastatic colorectal cancer (mCRC)? KR HER2 amplification is found in approximately 3% […]

10/09/2018

Hematology & Oncology – Hematology & Oncology

The October issue of Clinical Advances in Hematology & Oncology is available on our website

  H&O What are some ethical concerns regarding the typical design of clinical trials in oncology? JK The risk/benefit ratio is an important concern. When treating […]

08/22/2018

Hematology & Oncology – Hematology & Oncology

The August issue is now available on our site

  H&O Which patients with melanoma are at elevated risk for a recurrence after surgical resection? JW A patient at elevated risk is one whose 5-year […]

07/20/2018

Hematology & Oncology – Hematology & Oncology

The July issue of Clinical Advances in Hematology & Oncology is available on our website

  H&O What treatments are available for patients with sickle cell disease? KA Sickle cell disease (SCD) can be cured with allogeneic hematopoietic stem cell transplant. […]

06/18/2018

MMP Archive – Hematology & Oncology

See the articles from our newest (June) issue

  H&O What is bipolar androgen therapy (BAT)? SD BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control […]

04/27/2018

Hematology & Oncology – Hematology & Oncology

The April issue is now available on our website -- check it out!

H&O Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]

03/21/2018

Current Issue – Hematology & Oncology

Be sure to read the March issue of Clinical Advances in Hematology & Oncology, now on our website

H&O How common is thrombosis in patients being treated for cancer? MS Approximately 20% to 25% of patients with venous thromboembolism (VTE) at a typical […]

02/14/2018

Current Issue – Hematology & Oncology

Check out the February issue of Clinical Advances in Hematology & Oncology, which is now on our website

H&O What is considered the standard adjuvant treatment for stage III BRAF-mutated melanoma? GL The standard treatment for patients with stage III BRAF-mutated melanoma after […]

02/01/2018

Current Issue – Hematology & Oncology

The January issue of Clinical Advances in Hematology & Oncology is available on our website. https://buff.ly/2s1L2Ri

H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]

01/05/2018

Current Issue – Hematology & Oncology

Be sure to check out the December issue of Clinical Advances in Hematology and Oncology on our website

H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]

11/17/2017

MMP Archive – Hematology & Oncology

The November issue of Clinical Advances in Hematology & Oncology is on our site

H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

11/01/2017

Letter from the Editor: How to Treat Hodgkin Lymphoma – Hematology & Oncology

Letter from the Editor: How to treat Hodgkin lymphoma, by Brad S. Kahl, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Letter from the Editor: How to Treat Hodgkin Lymphoma Brad S. Kahl, MD Download PDF Last weekend, I attended the 2017 ASH Meeting on Hematologic Malignancies. This is an incredible 2-day meeting organized around a series...

10/30/2017

In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma – Hematology & Oncology

Encorafenib and binimetinib in BRAF-mutated melanoma, with Keith Flaherty, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma Keith Flaherty, MD Professor of Medicine Harvard Medical School Boston, Massachusetts Download PDF H&O What makes the BRAF inhibitor encorafenib plus…

10/30/2017

The Role of Genomics in Patients With Advanced Prostate Cancer – Hematology & Oncology

Genomics in advanced prostate cancer, with Maha H. Hussain, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 The Role of Genomics in Patients With Advanced Prostate Cancer Maha H. Hussain, MD Genevieve E. Teuton Professor of Medicine Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, Illi...

10/27/2017

When to Initiate Treatment in Smoldering Multiple Myeloma – Hematology & Oncology

When to initiate treatment in smoldering multiple myeloma, with María-Victoria Mateos, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 When to Initiate Treatment in Smoldering Multiple Myeloma María-Victoria Mateos, MD, PhD Director of the Myeloma Unit Haematology Department University Hospital of Salamanca Salamanca, Spain Download PDF H&O How is smold...

10/26/2017

Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer – Hematology & Oncology

DNA repair gene mutations in advanced prostate cancer, by Emmanuel S. Antonarakis, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD Dr Schweizer is an assistant professor in the Division of Oncology…

10/25/2017

Direct-to-Consumer Advertising of Cancer Treatments – Hematology & Oncology

Direct-to-consumer advertising of cancer treatments, with Lowell E. Schnipper, MD
http://www.hematologyandoncology.net/archives/october-2017/direct-to-consumer-advertising-of-cancer-treatments/

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Direct-to-Consumer Advertising of Cancer Treatments Lowell E. Schnipper, MD Theodore and Evelyn Berenson Distinguished Professor of Medicine in the Field of Oncology Harvard Medical School Clinical Director, Cancer Center…

10/25/2017

Current Challenges in the Management of Essential Thrombocythemia – Hematology & Oncology

The management of essential thrombocythemia, by Laura C. Michaelis, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Current Challenges in the Management of Essential Thrombocythemia Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD Corresponding author: Laura C. Michaelis, MD Hematology and Oncology Medical College of Wi...

10/25/2017

Hem/Onc News – Hematology & Oncology

New approvals for tisagenlecleucel (Kymriah, Novartis) and notuzumab ozogamicin (Besponsa, Pfizer), and reapproval for gemtuzumab ozogamicin (Mylotarg, Pfizer)

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Hem/Onc News Devon Schuyler Download PDF First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric a...

10/24/2017

What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? – Hematology & Oncology

The optimal duration of adjuvant therapy in colon cancer, with Anthony F. Shields, MD, PhD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? Anthony F. Shields, MD, PhD Professor of Medicine and Oncology Associate Center Director for Clinical Sciences Karmanos Cancer Institute, Wayne State Univer...

10/23/2017

How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver – Hematology & Oncology

How I treat stage IV non–small cell lung cancer in the absence of any actionable oncogenic driver, by Mark A. Socinski, MD
http://www.hematologyandoncology.net/archives/october-2017/how-i-treat-stage-iv-non-small-cell-lung-cancer-in-the-absence-of-any-actionable-oncogenic-driver/

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Download PDF Overview • T...

10/23/2017

MMP Archive – Hematology & Oncology

The October issue of Clinical Advances in Hematology & Oncology is now available

H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]